Northsight Capital plans to acquire Stargreen Holdings to expand its business and presence in the cannabis industry.

Based on the purchase consideration, Northsight expects the acquisition to cost between $5m and $20m.

"Based on the purchase consideration, Northsight expects the acquisition to cost between $5m and $20m."

The company will issue 210 million of its common stock shares to raise funds for the acquisition.

GL Capital Management and ABG Management plan to acquire SciClone Pharma for a purchase consideration of $570m.

The companies plan to fund the acquisition through debt and equity financing.

Morgan Stanley is acting as transaction adviser, and Skadden Arps, Slate Meagher &Flom and Fangda Law Firm are acting as legal advisers for the acquisition.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Tonghua Golden Horse Pharmaceutical Industry plans to acquire medicinal materials firm Lhasa.

The company expects the acquisition to cost up to $1.6m.

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now